Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-É'SYN biomarker test (formerly SYNTap) is the only seed amplification assay available to aid the diagnosis of synucleinopathies associated with Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body copathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/09/24 | $6,000,000 | Series B |
Eli Lilly and Company Formation Venture Engineering  | undisclosed |
